The global market for dipeptidyl peptidase-4 inhibitors is projected to expand to $14.78 billion by 2030, propelled by rising diabetes prevalence, increasing access to care, and the shift towards affordable oral therapies and generics, with major companies competing on scale and pricing.
The market for dipeptidyl peptidase-4 inhibitors is expected to keep expanding as diabetes rates climb worldwide and clinicians continue to favour treatments that are simple to take and easy to combine with other therapies. Research cited by Grand View Research puts the sector on course to reach $14.78 billion by 2030, implying a compound annual growth rate of 4.5%, with demand supported by the burden of type 2 diabetes, wider access to care in developing markets and a steady appetite for lower-cost glucose-control medicines.
That growth story is closely tied to the practical appeal of oral therapy. DPP-4 inhibitors remain widely used as add-on treatment in type 2 diabetes, particularly among older patients and in fixed-dose combinations, while the market is also shifting towards generic versions. The category spans products such as sitagliptin, saxagliptin, linagliptin, alogliptin and vildagliptin, with distribution moving through hospital pharmacies, retail outlets and online channels.
Corporate activity is reinforcing that trend. In August 2023, Lupin said it acquired the diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH in a deal valued at €26 million, including trademark rights. The move built on a co-marketing arrangement already in place in India, where Lupin has sold the brands since 2015. Boehringer Ingelheim had earlier partnered with Lupin to market linagliptin under ONDERO and ONDERO MET, while continuing to sell its own Trajenta products.
The competitive field is crowded, with major drugmakers including Merck & Co, AstraZeneca, Takeda, Bristol Myers Squibb, Novartis and several Indian generics specialists all active in the segment. For now, the market’s momentum appears less about breakthrough innovation than about scale, access and pricing: a large patient pool, the convenience of tablets and the growing use of combination regimens are keeping DPP-4 inhibitors relevant even as cheaper generic options gain ground.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
